Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Multiple sclerosis: pathogenesis and treatment.
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
Multiple sclerosis prevalence in the United States commercially insured population.
Other National MS Societies (Not listed here)
Pharmacokinetics and metabolism of mitoxantrone. A review.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Episode 15 with Professor Ludwig Kappos on the DECIDE trial of daclizumab versus interferon ë_-1a
endMS CONFERENCE
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
Novel MS Drugs Advance
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
8th World Congress on Controversies in Neurology (CONy)
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial

Pages